Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25403261 | 0.81 | — | — | |
| SCHEMBL18246890 | 0.74 | APLNR (1.00) | APLNRKMT2AMEN1NOS2 | |
| SCHEMBL18246892 | 0.74 | APLNR (1.00) | APLNRKMT2AMEN1NOS2 | |
| SCHEMBL3510562 | 0.74 | KMT2A (0.35) | APLNRKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL12678605 | 0.73 | APLNR (0.59) | APLNRKMT2AMEN1NOS2 | |
| SCHEMBL25023811 | 0.72 | ALDH1A1 (0.35) | APLNRKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL1483826 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL28549560 | 0.71 | ALDH1A1 (0.38) | KMT2AMEN1ALDH1A1MAPTGAA | |
| SCHEMBL3585742 | 0.71 | — | — | |
| SCHEMBL13505667 | 0.71 | KDM4E (0.46) | KMT2AMEN1ALDH1A1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11229636-B2 | Substituted tetrahydroquinolinone compounds as ROR gamma modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-01-25 | — | — | US | disclosed |
| US-20210113551-A9 | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229636-B2 | Substituted tetrahydroquinolinone compounds as ROR gamma modulators | RORC, RORA, RORB | APLNR 1766/4885KMT2A 2114/4885MEN1 4325/4885 |
| US-20210113551-A9 | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS | RORC, RORA, RORB | APLNR 1766/4885KMT2A 2114/4885MEN1 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.